Related scientific articles (all)

A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and Facilitators.

Authors : Kenis C, Heeren P, Decoster L, Van Puyvelde K, Conings G, Cornelis F, Cornette P, Moor R, Luce S, Libert Y, Van Rijswijk R, Jerusalem G, Rasschaert M, Langenaeken C, Baitar A, Specenier P, Geboers K, Vandenborre K, Debruyne PR, Vanoverbeke K, Van den Bulck H, Praet JP, Focan C, Verschaeve V, Nols N, Goeminne JC, Petit B, Lobelle JP, Flamaing J, Milisen K, Wildiers H
Year : 2016
Journal : J Nutr Health Aging
Volume : 20
Pages : 60-70

Rôle de corticostéroïdes dans le cancer de la prostate. Effet bénéfique ou néfaste ?

Authors : Martinez C, Sideris S, Roumeguere T, Van Velthoven R, Awada A, Costante G, Gil T
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(6)
Pages : 661-71

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

Authors : Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J
Year : 2016
Journal : Ann Oncol
Volume : 27
Pages : v111-v118

Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.

Authors : Sideris S, Aoun F, Zanaty M, Martinez NC, Latifyan S, Awada A, Gil T
Year : 2016
Journal : Mol Clin Oncol
Volume : 4
Pages : 1063-1067

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be th

Authors : Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, van t Veer L, Rutgers E, Piccart-Gebhart M, Stork-Sloots L, Dell orto P, Glas A, Cardoso F
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 155(3)
Pages : 463-9

Nutrition et prévention du cancer : changer les mentalités

Authors : Awada A
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Express approval of immune checkpoint inhibitors: a conflict between science and finance.

Authors : Kourie HR, Tabchi S, Kattan J
Year : 2016
Journal : Future Oncol
Volume : 12(10)
Pages : 1215-17

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Authors : Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27
Pages : 1021-7

Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance.

Authors : Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans ME, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R
Year : 2016
Journal : Clin Cancer Res
Volume : 22(21)
Pages : 5238-48

Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

Authors : Kourie HR, Awada G, Awada A
Year : 2016
Journal : Future Oncol
Volume : 12(4)
Pages : 429-31

Foreword

Authors : Awada A
Year : 2016
Journal : EMJ Oncology
Volume : 41
Pages : 11

Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

Authors : Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, Von Minckwitz G, Buyse M, Piccart-Gebhart M
Year : 2016
Journal : Ann Oncol
Volume : 27(6)
Pages : 1029-34

Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Authors : Drisis S, Metens T, Ignatiadis M, Stathopoulos K, Chao SL, Lemort M
Year : 2016
Journal : Eur Radiol
Volume : 26(5)
Pages : 1474-84

Bladder and vaginal transitional cell carcinoma: A case report.

Authors : Aoun F, Kourie HR, El Rassy E, Van Velthoven R
Year : 2016
Journal : Oncol Lett
Volume : 12
Pages : 2181-2183

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Authors : Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A
Year : 2016
Journal : Expert Opin Drug Metab Toxicol
Volume : 12(8)
Pages : 947-57

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Authors : Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart-Gebhart M, Gelber Rd
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 155
Pages : 127-32

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT0006

Authors : Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart-Gebhart M, Cameron D
Year : 2016
Journal : Eur J Cancer
Volume : 53
Pages : 144-54

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Authors : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Year : 2016
Journal : Ann Oncol
Volume : 27(4)
Pages : 619-24

What is the role of informed decision-making?

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(9)
Pages : 893